GlassScriptPhysician profile
Daniel P Greene
NPI 1386957876
$1,504.92
in general payments reported to CMS, 2019-2025
20 companies · $18.80 in 2025
The $18.80 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $70.74 · 2021: $171 · 2022: $339 · 2023: $220 · 2024: $236 · 2025: $18.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $333.28 | 2019-2024 | Cequa |
| Aerie Pharmaceuticals, INC. | $158.64 | 2019 | |
| Biotissue Holdings INC. | $148.92 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $114.84 | 2019-2023 | |
| United Therapeutics Corporation | $108.47 | 2024 | |
| Mallinckrodt Hospital Products INC. | $95.19 | 2022-2023 | Acthar |
| Oyster Point Pharma, INC. | $78.85 | 2022-2023 | Tyrvaya |
| Harrow Eye, LLC | $60.71 | 2024-2025 | Iheezo, Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.15 | 2019-2021 | |
| Alcon Vision LLC | $54.38 | 2022-2024 | Rocklatan |
| Bausch & Lomb Americas INC. | $51.33 | 2023-2024 | Miebo, Xiidra |
| Dompe US, INC. | $43.89 | 2020-2021 | |
| Sight Sciences, INC. | $35.56 | 2022-2024 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $32.90 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $31.32 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28.28 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $23.70 | 2019 | |
| Eyevance Pharmaceuticals LLC | $18.91 | 2021 | |
| Abbvie INC. | $16.50 | 2022 | |
| Omeros Corporation | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.